The attention deficit hyperactivity disorder (adhd) therapeutics global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The attention deficit hyperactivity disorder (ADHD) therapeutics market size has grown strongly in recent years. It will grow from $12.37 billion in 2023 to $13.21 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to diagnostic awareness and screening programs, rising incidence of ADHD, advancements in treatment modalities, healthcare infrastructure development, and health insurance coverage expansion.
The attention deficit hyperactivity disorder (ADHD) therapeutics market size is expected to see strong growth in the next few years. It will grow to $16.42 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to genetic research and personalized medicine, increasing mental health awareness, global and national mental health initiatives, telehealth expansion, integration of behavioral therapies. Major trends in the forecast period include technological innovations in treatment, research and development initiatives, digital therapeutics integration, precision medicine approaches, innovations in drug delivery systems.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/attention-deficit-hyperactivity-disorder-adhd-therapeutics-global-market-report
Scope Of Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Overview
Market Drivers –
The increasing prevalence of attention-deficit hyperactivity disorder is expected to propel the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutics market going forward. The rising prevalence of attention-deficit hyperactivity disorder (ADHD) refers to the growing number of individuals diagnosed with this neurodevelopmental disorder over time. ADHS therapeutics address the multifaceted nature of the condition, aiming to improve symptom management, functional impairment, quality of life, and overall well-being for individuals affected by ADHD. For instance, in January 2023, according to reports published by the Guardian, a US-based news publishing company, an estimated 170,000 identified patients were prescribed for ADHD in 2022, a 20.4% increase from the 141,000 identified patients during the same period in 2021. Therefore, the increasing prevalence of ADHD is driving the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutic market.
Market Trends –
Major companies operating in the attention-deficit hyperactivity disorder (ADHD) therapeutics market are focusing on the development of digital advancements such as Endeavor over-the-counter (OTC) versions of digital therapeutics for ADHD to meet increased demand for digital solutions and the rise in demand for remote healthcare. Digital therapeutics are evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. These interventions are designed to be used independently or with traditional medical treatments. For instance, in June 2023, Akili, a US-based digital health company, launched an over-the-counter (OTC) version of its video game-based digital therapeutic for adults with attention-deficit hyperactivity disorder (ADHD). The OTC version, EndeavorOTC, is designed to improve attention, time management, and organizational skills. Additionally, this move follows the success of Akili’s FDA-authorized prescription video game treatment, EndeavorRx, for children with ADHD. The OTC version provides adults with a non-drug treatment option for managing ADHD symptoms.
The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented –
1) By Drug Type: Stimulants, Non-Stimulants
2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy
3) By Age Group: Pediatric And Adolescent, Adult
4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce
Get an inside scoop of the attention deficit hyperactivity disorder (adhd) therapeutics market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp
Regional Insights –
North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical’s, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.
Table of Contents
1. Executive Summary
2. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report Structure
3. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trends And Strategies
4. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market – Macro Economic Scenario
5. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size And Growth
…..
27. Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
